Hims stock reversed lower Wednesday as analysts laid out low expectations for Him & Hers' branded tirzepatide.

The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a ...

Questions about insurance coverage for weight-loss drugs are getting more intense as cheaper alternatives go off the market.

Perez Hilton has struggled with weight management for decades. Now, he’s spreading the word about the benefits of GLP-1 drugs ...

If you’re looking into weight loss drugs, liraglutide has no doubt popped up. It’s a diabetes and weight loss medication sold ...

Meanwhile, the first major obesity-related phase 3 trial for orforglipron is set to complete in July. If the data from the ...

A recent study from the University of Pennsylvania has shown that the injectable drug semaglutide can help people lose a ...

Meghan Trainor is speaking out about the intense public focus on her appearance of late. After being honored over the weekend ...

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment ...

Shares of Hims & Hers Health (HIMS) rallied on Tuesday after the telehealth company said it would begin selling branded versions of Eli ...

A new study found that spending on GLP-1 medications such as Ozempic, Wegovy and Zepbound surged to $5.8 billion in 2022 ...

Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in ...